Biosupply Trends Marketplace News
Monday, December 16, 2019
biosupply button green pixel top of biosupply button
Biosupply, place your product order MyFluVaccine, place your vaccine order Verified Inventory Program, sign up for streamlined inventory

Recommended Vaccine Rates for Children Remain Steady in the U.S.

Main article image
 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

Two studies that examined vaccination coverage among young children in the U.S. has found vaccination rates are holding steady for those recommended by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. read more ]

New Practice Guidelines Now Available for ITP

The American Society of Hematology (ASH) has published new state-of-the-art guidelines for the treatment of immune thrombocytopenia (ITP), a rare bleed disorder characterized by a decrease in the number of platelets, the part of the blood needed for normal clotting. read more ]

Two Flu Strains in 2019-2020 Influenza Vaccine May Be a Mismatch

According to the World Health Organization (WHO), selections for the next Southern Hemisphere influenza (flu) vaccine suggest two of the four viruses, A/H3N2 and B/Victoria, in the Northern Hemisphere vaccine may not be optimally protective this flu season. Therefore, the WHO strain selection committee has concluded the strains need to be updated because the ones used in the Northern Hemisphere vaccine don't match the strains of the viruses that are now dominant, which is known as a "mismatch." read more ]

Industry News

 
Industry News Image
 

From Amgen

Amgen's biosimilar to Johnson & Johnson's rheumatoid arthritis drug, Remicade, has been approved by the U.S. Food and Drug Administration. The biosimilar, Avsola, has the same chemical components, dosage form and strength as Remicade and can treat a range of autoimmune disorders. read more ]

From Merck

The world's first Ebola vaccine, Ervebo, has been prequalified by the World Health Organization (WHO), meaning it meets WHO's quality, safety and efficacy standards.  [ read more ]

From Sandoz

The U.S. Food and Drug Administration has approved Ziextenzo (pegfilgrastim-bmez), the 24th biosimilar approval in the U.S. and the third biosimilar of Amgen's Neulasta.  [ read more ]

IVIG & Albumin Supply Index

IVIG and Albumin Days On Hand
     
 
 
 
     
 
   
  button to click to see FEIBA full prescribing information  
 
 

What's New at FFF

Ambrisentan  (Par Pharmaceutical)

Ambrisentan film-coated tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). It is supplied in 5 mg and 10 mg tablet strengths and is available in the following package configurations: 5 mg 10 count bottle, 5 mg 30 count bottle, 10 mg 10 count bottle and 10 mg 30 count bottle.

For more information about Ambrisentan, log in to biosupply.fffenterprises.com

Bosentan  (Par Pharmaceutical)

Bosentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%). It is available as a 62.5 mg tablet in a bottle containing 60 tablets and a 125 mg tablet in a bottle containing 60 tablets.

For more information about Bosentan, log in to biosupply.fffenterprises.com

Treprostinil  (Par Pharmaceutical)

Treprostinil injection is a prostacyclin vasodilator indicated for pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension in patients requiring transition from epoprostenol. It is supplied in 20 mL multidose vials as sterile solutions in water for injection, individually packaged in cartons, and is available in 1 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL concentrations.

For more information about Treprostinil, log in to biosupply.fffenterprises.com

KOATE  (Kedrion)

KOATE is indicated for the treatment of hemophilia A in which there is a demonstrated deficiency of activity of clotting factor VIII. Koate provides a means of temporarily replacing the missing clotting factor to control or prevent bleeding episodes, or to perform emergency and elective surgery on individuals with hemophilia. It is supplied in a kit containing one single-use vial of Koate lyophilized powder, one vial of sterile water for injection, USP, one sterile double-ended transfer needle, one sterile filter needle, and one sterile administration set.

For more information about KOATE, log in to biosupply.fffenterprises.com

ELCYS  (EXELA PHARMA SCIENCES)

ELCYS (cysteine hydrochloride injection) is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN) and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. Each 10 mL of ELCYS contains 500 mg of cysteine hydrochloride, USP (equivalent to 345 mg of cysteine) in water for injection. Sodium hydroxide and/or hydrochloric acid are used as needed to adjust the pH range from 1.0 to 2.5.

For more information about ELCYS, log in to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Oct. 1, 2019, through Dec. 31, 2019.

 
Calculate your current medicare IVIG/SCIG Rates
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Flebogamma J1572 $71.17 $70.03
Gammagard S/D J1566 $122.41 $120.44
Gammaplex J1557 $91.65 $90.18
Octagam J1568 $71.37 $70.22
Privigen J1459 $80.24 $78.96
SCIG
CUVITRU J1555 $137.87 $135.66
Hizentra J1559 $104.37 $102.70
HyQvia J1575 $145.56 $143.23
IVIG / SCIG
Gammagard Liquid J1569 $74.94 $73.73
Gammaked J1561 $78.28 $77.02
Gamunex-C J1561 $78.28 $77.02

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 
Log in to BioSupply for Immune Globulin Products

Resources

FFF customers may order the following complementary resources to help you with your practice:

Seasonal Flu Poster flu myths and facts brochure
immune globulin reference charts
•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to IG Living
IG Living Magazine cover
BioSupplyTrends Quarterly Magazine cover

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Subscribe to Biosupply Trends Quarterly Magazine
small Biosupply logo small MyFluVaccine logo Verified Inventory Program logo
Home | About | Advertise | Subscribe | Contact – ©FFF Enterprises, Inc.